| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Should you acquire Titan after the recent volatility decline?
 | By Vlad Skutelnik | Macroaxis Story |
It appears that Titan Pharmaceuticals may not have a good chance to recover from the recent decline as its shares fell again. This firm's current daily volatility is 8.93 percent, with a beta of 0.2 and an alpha of -1.03 over DOW. As many millenniums are trying to avoid the recent volatility, we are going to recap Titan Pharmaceuticals a little further to understand its historical price patterns. We will evaluate why we are still optimistic in anticipation of a recovery.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
Titan Pharmaceuticals currently holds about 5.5 M in cash with (16.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. The entity has a beta of 0.1956, which indicates not very significant fluctuations relative to the market. Let's try to break down what Titan's beta means in this case. As returns on the market increase, Titan Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Titan Pharmaceuticals will be expected to be smaller as well. Even though it is essential to pay attention to Titan Pharmaceuticals current price movements, it is always good to be careful when utilizing equity historical returns. Our philosophy towards measuring any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Titan Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate its performance. Titan Pharmaceuticals has an expected return of -0.91%. Please be advised to validate Titan Pharmaceuticals jensen alpha and semi variance to decide if Titan Pharmaceuticals stock performance from the past will be repeated at some point in the near future.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Titan Pharmaceuticals. Your research has to be compared to or analyzed against Titan Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Titan Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Titan Pharmaceuticals.
Investing in Titan Pharmaceuticals, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Titan Pharmaceuticals along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Titan Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Titan Pharmaceuticals's Liquidity
Titan Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Titan Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Titan Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Titan Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Titan Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Titan Pharmaceuticals's total debt and its cash.
Titan Pharmaceuticals Gross Profit
Titan Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Titan Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Titan Pharmaceuticals Gross Profit growth over the last 10 years. Please check Titan Pharmaceuticals' gross profit and other fundamental indicators for more details.
Titan Pharmaceuticals Correlation with Peers
Investors in Titan can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Titan Pharmaceuticals. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Titan Pharmaceuticals and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Titan is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Titan for more details
Breaking it down a bit more
Titan Pharmaceuticals owns Efficiency Ratio (i.e. Sharpe Ratio) of -0.1, which indicates the firm had -0.1% of return per unit of risk over the last month. Macroaxis standpoint towards measuring the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Titan Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to validate Titan Pharmaceuticals coefficient of variation of (887.72), and Risk Adjusted Performance of (0.13) to confirm the risk estimate we provide.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Titan Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.